No Data
No Data
BioCryst Pharmaceuticals(BCRX.US) Director Buys US$31,900 in Common Stock
$BioCryst Pharmaceuticals(BCRX.US)$ Director Hutson Nancy J purchased 5,000 shares of common stock on May 20, 2024 at an average price of $6.38 for a total value of $31,900.Source: Announcement What i
BioCryst Pharmaceuticals(BCRX.US) Director Buys US$93,750 in Common Stock
$BioCryst Pharmaceuticals(BCRX.US)$ Director MILANO VINCENT purchased 15,000 shares of common stock on May 20, 2024 at an average price of $6.25 for a total value of $93,750.Source: Announcement What
Sector Update: Health Care Stocks Advance Late Wednesday Afternoon
Health care stocks were rising late Wednesday afternoon, with the NYSE Health Care Index up 1% and the Health Care Select Sector SPDR Fund (XLV) adding 1.2%. The iShares Biotechnology ETF (IBB) climbe
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) fell sharply during Wednesday's session after the company reported first-quarter financial results.Bolt Biotherapeutics posted a GAAP loss of 28 cent
BioCryst Pharmaceuticals Shares Rise 20% Following Disclosure of Executive Share Purchases
BioCryst Pharmaceuticals (BCRX) shares were up nearly 20% in recent trading after the company reported in regulatory filings Wednesday that several of its executives purchased shares in the company ea
BioCryst Pharmaceuticals Form 4 Filings Shows CCO Charles K Gayer Bought 30,000 Shares At An Average Price Of $5.47/Share; CEO Jon P Stonehouse Bought 30,000 Shares At An Average Price Of $5.55/Share; Steven K Galson Bought 21,940 Shares At An Average...
BioCryst Pharmaceuticals Form 4 Filings Shows CCO Charles K Gayer Bought 30,000 Shares At An Average Price Of $5.47/Share; CEO Jon P Stonehouse Bought 30,000 Shares At An Average Price Of $5.55/Share;
No Data